StockData

Azitra vs CervoMed

AZTR and CRVO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AZTR and CRVO compare

Azitra is the larger company, worth 1.6 times as much as CervoMed ($36.8M against $22.7M).

CervoMed scores higher on the StockData Score (5 against 1 for Azitra), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAZTRCRVO
Size and price
Market cap$36.8M$22.7M
Share price$0.608$1.50
Change, 1 year67.0%−80.5%
Change, 5 years–−94.9%
Beta (5Y)–3.41
Employees1315
StockData Score
Total score15 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score14 (better)
Dividend score00
Valuation
P/S–68.5×
P/B5.0×1.0× (better)
FCF yield−30.3%–
Growth
Revenue growth (TTM)–−95.7%
Profitability
Operating margin–−9407%
Net margin–−9161%
Return on equity−257%−108% (better)
Return on invested capital−1090%–
Financial health
Debt / equity–0.00
Interest coverage−1164.7×–
Current ratio4.86–
Altman Z-score−1.70 (better)−5.50
Piotroski F-score11
Dividends and buybacks
Buyback yield−14.8%–
Shareholder yield−14.8%0.00% (better)
Ownership
Held by institutions35.7%11.6%
Held by insiders9.6%36.9%
Insider net buying, 12 months–$3.0M
Short interest, % of float0.56%12.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.